HLX-403

N/A

Report date: 2026/05/18 20:02:07

Base Information

Drug NameHLX-403

Drug Alias NameHLX403HLX-403

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Camptothecin derivative payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker

Mechanisms of ActionAnti-Cadherin-17DNA topoisomerase I inhibitors

TargetsCadherin-17DNA topoisomerase I

Therapy Area/IndicationsGastrointestinal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesShanghai Henlius Biotech Inc

China Registration ClassN/A

Develop Information

Active CompaniesShanghai Henlius Biotech Inc

Inactive CompaniesN/A

Active IndicationsGastrointestinal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A